Small interfering RNA-induced silencing of galectin-3 inhibits the malignant phenotypes of osteosarcoma in vitro Retraction in /10.3892/mmr.2021.12309

Lei,Pengfei; He,Hongbo; Hu,Yihe; Liao,Zhan

doi:10.3892/mmr.2015.4165

Small interfering RNA-induced silencing of galectin-3 inhibits the malignant phenotypes of osteosarcoma in vitro

Retraction in: /10.3892/mmr.2021.12309

Authors:
- Pengfei Lei
- Hongbo He
- Yihe Hu
- Zhan Liao
View Affiliations

Affiliations: Department of Orthopedics, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China
Published online on: July 31, 2015 https://doi.org/10.3892/mmr.2015.4165
Pages: 6316-6322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is the most common malignant tumor of bone. It has recently been demonstrated that galectin-3, a multifunctional β-galactoside-binding, is significantly upregulated in OS tissues, and is correlated with its progression and metastasis. However, the detailed role of galectin‑3 in the regulation of cellular biological processes in OS cells has remained to be elucidated. The present study reported that the mRNA and protein levels of galectin‑3 were significantly increased in OS tissues compared to those in their matched normal adjacent tissues. Furthermore, galectin‑3 was upregulated in three OS cell lines, Saos‑2, MG63 and U2OS, when compared with that in the human osteoblast cell line hFOB1.19. Knockdown of galectin‑3 by galectin‑3‑specific small interfering RNA markedly inhibited OS‑cell proliferation and induced cell apoptosis. Furthermore, silencing of galectin‑3 expression significantly inhibited OS cell migration and invasion, accompanied with a marked decrease in the protein expression of matrix metalloproteinase 2 and ‑9. Mechanistic investigation suggested that the mitogen‑activated protein kinase kinase/extracellular signal‑regulated protein kinase signaling pathway may be involved in the galectin‑3‑mediated OS cell invasion. In conclusion, the present study was the first to report that silencing of galectin‑3 inhibited the malignant phenotypes of osteosarcoma in vitro. Therefore, galectin-3 may serve as a potential therapeutic target for OS.

View Figures

View References

1	Thompson LD: Osteosarcoma. Ear Nose Throat J. 92:288–290. 2013.PubMed/NCBI
2	Yang J and Zhang W: New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406. 2013. View Article : Google Scholar : PubMed/NCBI
3	Fortuna-Costa A, Gomes AM, Kozlowski EO, Stelling MP and Pavão MS: Extracellular galectin-3 in tumor progression and metastasis. Front Oncol. 4:1382014. View Article : Google Scholar : PubMed/NCBI
4	Viguier M, Advedissian T, Delacour D, Poirier F and Deshayes F: Galectins in epithelial functions. Tissue Barriers. 2:e291032014. View Article : Google Scholar : PubMed/NCBI
5	Laderach DJ, Gentilini L, Jaworski FM and Compagno D: Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers. Prostate Cancer. 2013:5194362013. View Article : Google Scholar : PubMed/NCBI
6	Eisa NH, Ebrahim MA, Ragab M, Eissa LA and El-Gayar AM: Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma. J Oncol Pharm Pract. 2014.Epub ahead of print. PubMed/NCBI
7	von Klot CA, Kramer MW, Peters I, Hennenlotter J, Abbas M, Scherer R, Herrmann TR, Stenzl A, Kuczyk MA, Serth J and Merseburger AS: Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma. BMC Clin Pathol. 14:152014. View Article : Google Scholar : PubMed/NCBI
8	Zhou X, Jing J, Peng J, Mao W, Zheng Y, Wang D, Wang X, Liu Z and Zhang X: Expression and clinical significance of galectin-3 in osteosarcoma. Gene. 546:403–407. 2014. View Article : Google Scholar : PubMed/NCBI
9	Hou F, Wang L, Wang H, Gu J, Li M, Zhang J, Ling X, Gao X and Luo C: Elevated gene expression of S100A12 is correlated with the predominant clinical inflammatory factors in patients with bacterial pneumonia. Mol Med Rep. 11:4345–4352. 2015.PubMed/NCBI
10	Gao J, Ding F, Liu Q and Yao Y: Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem. 376:21–32. 2013. View Article : Google Scholar
11	Miao JH, Wang SQ, Zhang MH, Yu FB, Zhang L, Yu ZX and Kuang Y: Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway. Oncol Rep. 32:1497–1504. 2014.PubMed/NCBI
12	Tsubaki M, Satou T, Itoh T, Imano M, Ogaki M, Yanae M and Nishida S: Reduction of metastasis, cell invasion and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol Appl Pharmacol. 259:402–410. 2012. View Article : Google Scholar : PubMed/NCBI
13	Diao CY, Guo HB, Ouyang YR, Zhang HC, Liu LH, Bu J, Wang ZH and Xiao T: Screening for metastatic osteosarcoma biomarkers with a DNA microarray. Asian Pac J Cancer Prev. 15:1817–1822. 2014. View Article : Google Scholar : PubMed/NCBI
14	Gao P, Simpson JL, Zhang J and Gibson PG: Galectin-3: Its role in asthma and potential as an anti-inflammatory target. Respir Res. 14:1362013. View Article : Google Scholar : PubMed/NCBI
15	Sundblad V, Croci DO and Rabinovich GA: Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues. Histol Histopathol. 26:247–265. 2011.
16	Funasaka T, Raz A and Nangia-Makker P: Galectin-3 in angio-genesis and metastasis. Glycobiology. 24:886–891. 2014. View Article : Google Scholar : PubMed/NCBI
17	Leal MF, Calcagno DQ, Chung J, de Freitas VM, Demachki S, Assumpção PP, Chammas R, Burbano RR and Smith MC: Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients. Clin Exp Med. 2014.Epub ahead of print.
18	Truran PP, Johnson SJ, Bliss RD, Lennard TW and Aspinall SR: Parafibromin, galectin-3, PGP9.5, Ki67 and cyclin D1: Using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 38:2845–2854. 2014. View Article : Google Scholar : PubMed/NCBI
19	Mirandola L, Nguyen DD, Rahman RL, Grizzi F, Yuefei Y, Figueroa JA, Jenkins MR, Cobos E and Chiriva-Internati M: Anti-Galectin-3 therapy: A new chance for multiple myeloma and ovarian cancer? Int Rev Immunol. 33:417–427. 2014. View Article : Google Scholar : PubMed/NCBI
20	van den Brûle F, Califice S and Castronovo V: Expression of galectins in cancer: A critical review. Glycoconj J. 19:537–542. 2004. View Article : Google Scholar : PubMed/NCBI
21	Zheng D, Hu Z, He F, Gao C, Xu L, Zou H, Wu Z, Jiang X and Wang J: Downregulation of galectin-3 causes a decrease in uPAR levels and inhibits the proliferation, migration and invasion of hepatocellular carcinoma cells. Oncol Rep. 32:411–418. 2014.PubMed/NCBI
22	Huang CX, Zhao JN, Zou WH, Li JJ, Wang PC, Liu CH and Wang YB: Reduction of galectin-3 expression reduces pituitary tumor cell progression. Genet Mol Res. 13:6892–6898. 2014. View Article : Google Scholar : PubMed/NCBI
23	Wang Y, Balan V, Kho D, Hogan V, Nangia-Makker P and Raz A: Galectin-3 regulates p21 stability in human prostate cancer cells. Oncogene. 32:5058–5065. 2013. View Article : Google Scholar
24	Kosacka M, Piesiak P, Kowal A, Golecki M and Jankowska R: Galectin-3 and cyclin D1 expression in non-small cell lung cancer. J Exp Clin Cancer Res. 30:1012011. View Article : Google Scholar : PubMed/NCBI
25	Zhang D, Chen ZG, Liu SH, Dong ZQ, Dalin M, Bao SS, Hu YW and Wei FC: Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating β-catenin. Acta Pharmacol Sin. 34:176–184. 2013. View Article : Google Scholar
26	Song S, Ji B, Ramachandran V, Wang H, Hafley M, Logsdon C and Bresalier RS: Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One. 7:e426992012. View Article : Google Scholar : PubMed/NCBI